1. SGLT6 - A pharmacological target for the treatment of obesity?
- Author
-
Baader-Pagler T, Eckhardt M, Himmelsbach F, Sauer A, Stierstorfer BE, and Hamilton BS
- Subjects
- Animals, Anti-Obesity Agents pharmacokinetics, Anti-Obesity Agents therapeutic use, Caco-2 Cells, Food Preferences drug effects, Glucose metabolism, HEK293 Cells, Humans, Inositol metabolism, Male, Mice, Mice, Inbred C57BL, Molecular Targeted Therapy, Anti-Obesity Agents pharmacology, Heat-Shock Proteins antagonists & inhibitors, Heat-Shock Proteins metabolism, Obesity drug therapy, Obesity metabolism, Symporters antagonists & inhibitors, Symporters metabolism
- Abstract
Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.
- Published
- 2018
- Full Text
- View/download PDF